Advertisement

PharmacoEconomics & Outcomes News

, Volume 820, Issue 1, pp 20–20 | Cite as

Ipilimumab/nivolumab cost effective in advanced melanoma

Clinical study
  • 3 Downloads

Reference

  1. Quon PL, et al. Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada. PharmacoEconomics-Open : 8 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-018-0112-1

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations